Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Outlook Therapeutics, a U.S.-based biopharmaceutical company focused on ophthalmic treatments for retina diseases, successfully closed a $5.0 million public offering by selling 20 million common shares with accompanying warrants. The funds raised will primarily support working capital and general corporate activities. The company is developing LYTE…